160 related articles for article (PubMed ID: 37787381)
21. Real-World Evidence for Regulatory Decision-Making: Guidance From Around the World.
Burns L; Roux NL; Kalesnik-Orszulak R; Christian J; Hukkelhoven M; Rockhold F; O'Donnell J
Clin Ther; 2022 Mar; 44(3):420-437. PubMed ID: 35181179
[TBL] [Abstract][Full Text] [Related]
22. ISPOR, the FDA, and the Evolving Regulatory Science of Medical Device Products.
O'Neill T; Miksad R; Miller D; Maloney L; John A; Hiller C; Hornberger J
Value Health; 2019 Jul; 22(7):754-761. PubMed ID: 31277820
[TBL] [Abstract][Full Text] [Related]
23. Nonrandomized Real-World Evidence to Support Regulatory Decision Making: Process for a Randomized Trial Replication Project.
Franklin JM; Pawar A; Martin D; Glynn RJ; Levenson M; Temple R; Schneeweiss S
Clin Pharmacol Ther; 2020 Apr; 107(4):817-826. PubMed ID: 31541454
[TBL] [Abstract][Full Text] [Related]
24. Organized structure of real-world evidence best practices: moving from fragmented recommendations to comprehensive guidance.
Jaksa A; Wu J; Jónsson P; Eichler HG; Vititoe S; Gatto NM
J Comp Eff Res; 2021 Jun; 10(9):711-731. PubMed ID: 33928789
[TBL] [Abstract][Full Text] [Related]
25. Using Real-World Data in the Health Technology Assessment of Pharmaceuticals: Strengths, Difficulties, and a Pragmatic Way Forward.
Akehurst R; Murphy LA; Solà-Morales O; Cunningham D; Mestre-Ferrandiz J; de Pouvourville G
Value Health; 2023 Apr; 26(4S):11-19. PubMed ID: 36706952
[TBL] [Abstract][Full Text] [Related]
26. Transparency in real-world evidence (RWE) studies to build confidence for decision-making: Reporting RWE research in diabetes.
Patorno E; Schneeweiss S; Wang SV
Diabetes Obes Metab; 2020 Apr; 22 Suppl 3(Suppl 3):45-59. PubMed ID: 32250527
[TBL] [Abstract][Full Text] [Related]
27. Understanding the challenge of comparative effectiveness research in focal epilepsy: A review of network meta-analyses and real-world evidence on antiepileptic drugs.
Thieffry S; Klein P; Baulac M; Plumb J; Pelgrims B; Steeves S; Borghs S
Epilepsia; 2020 Apr; 61(4):595-609. PubMed ID: 32201951
[TBL] [Abstract][Full Text] [Related]
28. Use of real-world evidence in regulatory decisions for rare diseases in the United States-Current status and future directions.
Wu J; Wang C; Toh S; Pisa FE; Bauer L
Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1213-1218. PubMed ID: 32003065
[TBL] [Abstract][Full Text] [Related]
29. Payer perceptions of the use of real-world evidence in oncology-based decision making.
Brixner D; Biskupiak J; Oderda G; Burgoyne D; Malone DC; Arondekar B; Niyazov A
J Manag Care Spec Pharm; 2021 Aug; 27(8):1096-1105. PubMed ID: 34337998
[No Abstract] [Full Text] [Related]
30. Is Real-World Evidence Used in P&T Monographs and Therapeutic Class Reviews?
Hurwitz JT; Brown M; Graff JS; Peters L; Malone DC
J Manag Care Spec Pharm; 2020 Dec; 26(12):1604-1611. PubMed ID: 33251991
[TBL] [Abstract][Full Text] [Related]
31. Awareness, Knowledge, and Utility of RCT Data vs RWE: Results From a Survey of US Cardiologists: Real-world Evidence in Clinical Decision Making.
Villines TC; Cziraky MJ; Amin AN
Clin Med Insights Cardiol; 2020; 14():1179546820953410. PubMed ID: 32952404
[TBL] [Abstract][Full Text] [Related]
32. Is Real-World Evidence Used in P&T Monographs and Therapeutic Class Reviews?
Hurwitz JT; Brown M; Graff JS; Peters L; Malone DC
J Manag Care Spec Pharm; 2017 Jun; 23(6):613-620. PubMed ID: 28530524
[TBL] [Abstract][Full Text] [Related]
33. A Structured Process to Identify Fit-for-Purpose Study Design and Data to Generate Valid and Transparent Real-World Evidence for Regulatory Uses.
Gatto NM; Vititoe SE; Rubinstein E; Reynolds RF; Campbell UB
Clin Pharmacol Ther; 2023 Jun; 113(6):1235-1239. PubMed ID: 36871138
[TBL] [Abstract][Full Text] [Related]
34. Evaluating and improving real-world evidence with Targeted Learning.
Gruber S; Phillips RV; Lee H; Concato J; van der Laan M
BMC Med Res Methodol; 2023 Aug; 23(1):178. PubMed ID: 37533017
[TBL] [Abstract][Full Text] [Related]
35. Demonstrating that Real World Evidence Is Fit-For-Purpose to Support Labeling: Parallels to Patient Reported Outcomes in the Pursuit of Labeling Claims.
Girman CJ; Ritchey ME; McNeill AM; Sundell KA; Meyer RJ
Ther Innov Regul Sci; 2021 May; 55(3):561-567. PubMed ID: 33507517
[TBL] [Abstract][Full Text] [Related]
36. Use of Clinical Data Interchange Standards Consortium (CDISC) Standards for Real-world Data: Expert Perspectives From a Qualitative Delphi Survey.
Facile R; Muhlbradt EE; Gong M; Li Q; Popat V; Pétavy F; Cornet R; Ruan Y; Koide D; Saito TI; Hume S; Rockhold F; Bao W; Dubman S; Jauregui Wurst B
JMIR Med Inform; 2022 Jan; 10(1):e30363. PubMed ID: 35084343
[TBL] [Abstract][Full Text] [Related]
37. Translational hurdles with cannabis medicines.
Graham M; Lucas CJ; Schneider J; Martin JH; Hall W
Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1325-1330. PubMed ID: 32281186
[TBL] [Abstract][Full Text] [Related]
38. Conducting Real-world Evidence Studies on the Clinical Outcomes of Diabetes Treatments.
Schneeweiss S; Patorno E
Endocr Rev; 2021 Sep; 42(5):658-690. PubMed ID: 33710268
[TBL] [Abstract][Full Text] [Related]
39. Real-world data: a comprehensive literature review on the barriers, challenges, and opportunities associated with their inclusion in the health technology assessment process.
Zisis K; Pavi E; Geitona M; Athanasakis K
J Pharm Pharm Sci; 2024; 27():12302. PubMed ID: 38481726
[No Abstract] [Full Text] [Related]
40. Meta-analyses using real-world data to generate clinical and epidemiological evidence: a systematic literature review of existing recommendations.
Briere JB; Bowrin K; Taieb V; Millier A; Toumi M; Coleman C
Curr Med Res Opin; 2018 Dec; 34(12):2125-2130. PubMed ID: 30217138
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
